Content area

|
|

Klinisk anvendelse af antimüllersk hormon i fertilitetsbehandling

Forfatter(e)
Fie Pilsgaard1, Anna Garcia-Alix Grynnerup2, Kristine Løssl1 & Anja Pinborg1 1) Fertilitetsklinikken, Gynækologisk/obstetrisk Afdeling, Hvidovre Hospital 2) Klinisk Biokemisk Afdeling, Hvidovre Hospital Ugeskr Læger 2017;179:V02170099
Reference: 
Ugeskr Læger 2017;179:V02170099
Blad nummer: 
Sidetal: 
2-5
The use of anti-Müllerian hormone in fertility treatment
The need for fertility treatment in Denmark is increasing, one of the main causes being postponed parenthood. Ovarian reserve is determined by the anti-Müllerian hormone (AMH) level and by antral follicle count. Both tests can predict the ovarian response to gonadotropin treatment prior to in vitro fertilization (IVF) and are used to individualize ovarian stimulation to achieve an appropriate number of follicles and to avoid ovarian hyperstimulation. A new assay detects low values of AMH and may predict who will benefit from IVF and who should be referred directly to oocyte donation.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Camilla Bang | 21/10
3 kommentarer
af Anne Gersdorff Korsgaard | 20/10
1 Kommentar
af Karen Brink Linnet | 19/10
1 Kommentar
af Thor Andersen Knudsen | 19/10
2 kommentarer
af Ole Lindgård Dollerup | 18/10
1 Kommentar
af Kristine Rasmussen | 18/10
1 Kommentar
af Camilla Bang | 16/10
1 Kommentar
af Tobias Ramm Eberlein | 15/10
6 kommentarer